Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Leronlimab |
Trade Name | |
Synonyms | PRO140|PRO 140|anti-CCR5 antibody |
Drug Descriptions |
Leronlimab is a monoclonal antibody that targets CCR5, which potentially induces killing of tumor cells expressing CCR5, inhibits invasion and metastasis, and reduces tumor burden (Cancer Res 2020;80(4 Suppl):Abstract nr PD4-04). |
DrugClasses | |
CAS Registry Number | 674782-26-4 |
NCIT ID | C137824 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Carboplatin + Leronlimab | Carboplatin Leronlimab | 0 | 1 |
Leronlimab | Leronlimab | 0 | 1 |